Pelizaeus Merzbacher syndrome: brief review of the literature
DOI:
https://doi.org/10.31157/an.v22i4.167Keywords:
Myelin, Demyelinating diseases, Pelizaeuz-Merzbacher, LeukopathiesAbstract
Introduction: Myelin diseases have been described since the 19th century, leucodsitrophiaes are a heterogeneous group of diseases, of progressive course, that can manifest a wide range of symptoms and complications, mostly of genetic aetiology, being Syndrome of Pelizaeuz Merzbacher, of inheritance linked to the X chromosome, the most frequent of these. Objective: provide an up-to-date overview of the epscial demyelinating diseases of the Pelizaeuz Merzbacher syndrome. Material and method: the most relevant articles considered by the authors were selected in PubMed; EBSCO; Thomson Reuters and OvidSP. Results: Merzbacher Pelizaeuz Syndrome presents important clinical heterogeneity and unfortunately at the moment does not have an effective treatment, however new stem cell technologies provide opportunities for its treatment.Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez
This work is licensed under a Creative Commons Attribution 4.0 International License.
September 2022-present © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January-September 2022 © The authors. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January 2014-December 2021 © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.